Page 43 - MemoriaCIBER-2018ENG

Arterial Pathology, Myocardial Ischaemia and Structural Heart Pathology
Coordinators:
David García-Dorado Alberto San Román
CIBERCV Programme 2 focussing on arterial diseases, myocardial ischaemia-reperfusion and structural cardiopathy has enjoyed a successful 2018 in which some important studies have been published as a result of the cooperation between different groups in the network, as well as getting under way some relevant projects.
In the line of research into Myocardial Ischaemia and Reperfusion, we should stress the study entitled “Ryanodine Receptor Glycation Favors Mitochondrial Damage in the Senescent Heart”, published in journal Circulation in which the cooperation between CIBERCV groups has shown that the mitochondria of senescent hearts develop a calcium overload as well as the part coming from the sarcoplasmic reticulum. The study has shown the mechanisms causing damage to the senescent myocardium, thus opening the way up to potential new therapeutic targets. The type of mechanistic studies led
to patents and contracts for developing new therapies such as the inhibition of calpain in ventricular remodelling. In order to increase the strength and speed of translation of knowledge to patients and society,we have set up a platform for preclinical studies in lesions caused by ischaemia-reperfusion, the CIBERCLAP platform, in which the groups taking part share standardised experimental biochemical, molecular and morphological
Cardiovascular Epidemiology and Risk Factors
Coordinator:
Jaume Marrugat
studies and imaging methods with centralised randomisation installations and central laboratories. With regard to clinical studies, some ambitious randomised and multi- centre assays have been carried out on patients with acute myocardial infarctions, such as the COMBAT-MI tests (including
360 patients) and REBOOT (> 500 patients already included), in which many hundreds of patients have already been included, as well as major registries in acute coronary syndrome in cooperation with Programme 4, such as ATHOS.
The line of research focussing on diseases
of the aortic valve includes mechanical cooperation studies to find out the molecular pathways leading to aortic dilation, the analysis of advanced images (a prominent one being CMR 4D, wall tension) of mechanical factors promoting dilation, and studies
of genetic factors modulating dilation
in genetics and acquired aortic diseases. Secondly, some large-scale cooperative multi-centre registries have been set up
and academic clinical tests for studying the evolution of aortic stenosis (> 1400 patients), the ones determining the appearance and result of acute aortic syndrome (RESA III study,> 600 patients included),or the utility of atorvastatin for preventing aortic dilation in patients with bicuspid aortic valve (BICATOR, 220 patients included).
In the line of research focussing on valve disease and congenital heart disease, the main multi-centre studies under way include population studies on the prevalence of adults with congenital heart disease (ACHD) and on mortality and sudden death in ACHD, and a registry of patients with ACHD and synchronisation therapy (RETRACCA), as well as studies on N-glycosylation in congenital heart diseases (CARDIoG) and re-enervation after an atrial switch operation.
The purpose of the Programme on Cardiovascular Epidemiology and Risk Factors is to investigate the mechanism linking cardiovascular risk factors with the serious illnesses entailed by these such as ischaemic cardiopathy and cerebrovascular disease, for example. Programme 3 of the CIBERCV consists of two research lines.
Within the line of Epidemiology, cohorts,
43
CIBERCV | ANNUAL REPORT 2018